Search

everythinglearnresearchcommunity

for

Search:↓

These migraine prevention drugs can cause side effects like constipation, hair loss, injection site reactions, fatigue, and sometimes unexpected issues like Raynaud's phenomenon and weight gain.

Ifidancitinib, a JAK inhibitor, effectively regrows hair in mice with alopecia by tiring out harmful T cells.

Janus kinase inhibitors can help children with alopecia areata regrow hair but may have some risks.

Epiduo® is an effective first-line acne treatment that reduces inflammation and combats antibiotic resistance.

Imiquimod can cause rare skin side effects, some irreversible, and long-term follow-up is important for users.

New findings suggest potential treatments for melanoma, hyperpigmentation, hair defects, and multiple sclerosis, and show skin microbiome changes don't cause atopic dermatitis.

JAK inhibitors are safe and effective for treating moderate-to-severe alopecia areata.

JAK inhibitors do not increase cancer risk in severe alopecia areata compared to traditional treatments.

Adapalene 0.1% effectively reduces acne by decreasing comedones and altering skin properties.

Adalimumab may cause severe hair loss in some patients.

Cyclosporine is effective for skin conditions but has declined in use due to toxicity concerns.

CEFFE injections effectively and safely improve postinflammatory hyperpigmentation.

Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.

Oral Janus kinase inhibitors may be an effective treatment option for lichen planopilaris with some risk of increased cholesterol and liver enzyme levels.

A CCS patient with severe complications was successfully treated using combined therapies.

Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.

Pioglitazone, Trimipramine, and Dimetindene may be repurposed to treat psoriasis.

Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.

DHT may reduce inflammation caused by certain bacteria in skin cells.

Tocilizumab therapy may cause skin and hair conditions like halo naevi, vitiligo, and alopecia areata.

Baricitinib is effective and safe for treating severe alopecia areata.

Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.

Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.

Topical ruxolitinib may help some skin conditions but needs more research for alopecia areata.

The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.

Tofacitinib helped psoriasis but not alopecia universalis, needing more research.

Some cells may slow melanoma growth, a protein could affect skin pigmentation, a gene-silencing method might treat hair defects, skin bacteria changes likely result from eczema, and a defensin protein could help treat multiple sclerosis.

A man had a rare skin reaction from a hair loss medication, which improved after stopping the drug.